<DOC>
	<DOCNO>NCT01273480</DOCNO>
	<brief_summary>The purpose study evaluate potential effect rifampin blood level trabectedin administration patient advanced malignancy .</brief_summary>
	<brief_title>A Study Assess Potential Effects Rifampin Pharmacokinetics Trabectedin Patients With Advanced Malignancies</brief_title>
	<detailed_description>This open-label study ( patient know name study drug receive ) , randomize ( patient assign 1 2 treatment sequence chance ) design examine pharmacokinetics ( blood level ) ass survival safety trabectedin coadministered rifampin patient advanced malignancy . Study drug include trabectedin rifampin . Trabectedin drug develop treat patient cancer administer intravenously ( i.v . ) catheter ( tube ) central vein period 3 hour every 28 day without rifampin . Rifampin antibiotic may interfere action trabectedin take orally ( mouth ) capsule . In addition , dexamethasone , drug use prevent nausea vomit chemotherapy patient may protective effect liver , administer patient administration trabectedin . In study , 3 patient initially randomize sequentially Treatment Sequence 1 Treatment Sequence 2 evaluate safety . If safety pharmacokinetic data collect 3 patient deem acceptable , additional patient randomize 1 2 treatment sequence . Patients complete treatment phase study discontinue due rifampin toxicity , opinion investigator would derive overall clinical benefit treatment trabectedin , opportunity continue treatment trabectedin optional extension phase . The dose schedule trabectedin may modify treat physician optional extension phase appropriate type malignancy treat . Patients receive 20 mg i.v . dexamethasone ( equivalent ) prior trabectedin administration cycle . Patients randomize Sequence 1 receive rifampin 600mg 1X daily ( 6 dos ) +trabectedin 1.3 mg/m2 i.v . follow 28 day later trabectedin 1.3 mg/m2 i.v . Patients randomize Sequence 2 receive trabectedin 1.3 mg/m2 i.v . follow 28 day later rifampin 600mg 1X daily ( 6 dos ) +trabectedin 1.3mg/m2 i.v . Dexamethasone 20 mg i.v. , equivalent administer 30 minute prior trabectedin administration .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Patients locally advance metastatic disease , solid tumor except hepatocellular carcinoma , relapse progressive disease follow standard care treatment chemotherapy prior enrollment , intolerant prior standard care treatment chemotherapy Patients Eastern Cooperative Oncology Group ( ECOG ) score &lt; =2 Patients able receive dexamethasone Patients hepatic function variable : total bilirubin &lt; =upper limit normal ( ULN ) , alkaline phosphatase ( ALP ) &lt; =1.5 ULN liver function test result ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] ) &lt; =2.5x ULN Patients previous exposure trabectedin Patients cancer metastasize ( spread ) central nervous system Patients know liver disease Patients myocardial infarct ( heart attack ) within 6 month enrollment clinically significant unstable medical condition assess Investigator Patients unable central catheter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Trabectedin , YONDELIS</keyword>
	<keyword>Rifampin ( RIFADIN )</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Locally advanced metastatic disease</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>